Dermatology

Early intervention beneficial for pediatric eczema or atopic dermatitis in infants.

Study findings contribute to the development of personalized treatment approaches for young children with eczema.

Crisaborole topical ointment shows promise in treating atopic dermatitis.

Top news of the day from across the health care landscape.

Dupilumab is an investigational antibody treatment for inadequately controlled moderate-to-severe atopic dermatitis.

Positive data from a pair of clinical trials announced at the 25th European Academy of Dermatology and Venereology Congress show Dupixent (dupilumab) is an effective option for moderate-to-severe atopic dermatitis.

Research presented at the 25th European Academy of Dermatology and Venereology Congress focused on the effects of crisaborole topical ointment in treating atopic dermatitis.

Results from clinical trials of Taltz presented at the European Academy of Dermatology and Venereology Congress.

New data for dupilumab presented at the 25th European Academy of Dermatology and Venereology Congress.

AbbVie’s experimental compound treats moderate-to-severe chronic plaque psoriasis.

Trial shows no increased incidence of adverse events or any new safety signals with exposure to Otezla.

Data presented at the European Academy of Dermatology and Venereology (EADV) Annual Congress shows safety and efficacy of apremilast (Otezla) over three years.

Amgen’s biosimilar Amjevita approved for variety of anti-inflammatory diseases, however, ongoing litigation may prevent it from hitting the market.

Refunds will be offered to plan sponsors if a patient discontinues a preferred anti-inflammatory drug within 90 days.

Allergan plans to acquire Vitae Pharmaceuticals and their experimental dermatology drugs.

New research compares cardiovascular issues among patients with type 2 diabetes and psoriasis.

Approximately 70% of patients with lesions had S. aureus colonization.

Debra Michaud, RN, MS, ARNP, FCP-C, MBA, senior clinician with MinuteClinic/CVS Health, lists the comorbidities that often accompany psoriasis.

Debra Michaud, RN, MS, ARNP, FCP-C, MBA, senior clinician with MinuteClinic/CVS Health, discusses the key counseling points associated with psoriasis therapies.

Debra Michaud, RN, MS, ARNP, FCP-C, MBA, senior clinician with MinuteClinic/CVS Health, outlines some of the major pharmacologic treatment options for psoriasis.

Immunotherapy for lung cancer patients may cause other conditions to become worse.

Specialty pharmacies may be able to better monitor comorbid conditions in psoriatic arthritis patients.

Ixekizumab fully or partially cleared moderate-to-severe psoriasis in 80% of patients.

Patients with psoriasis who are exposed to physical trauma face an elevated risk of developing psoriatic arthritis.

An experimental biologic known as brodalumab may prove to be an effective treatment for symptoms of psoriasis.

Recent study results have suggested that patients with psoriasis are at higher risk of developing major depression than those without the inflammatory skin condition.

Tofacitinib citrate (Xeljanz) treats adults with active psoriatic arthritis.

Dupilumab plus topical corticosteroids shows positive results in patients with inadequately controlled moderate-to-severe atopic dermatitis.

Approximately half of patients who received a high dose of the stem cells had reduced symptoms.